person · Reporting owner

ESSIG STUART

Disclosed activity across 8 companies

Tapewire entity: 41994
SEC CIK: 0001187574

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACCENDRA HEALTH INC/VA/OMI · Entity 6858	Director	June 28, 2019	July 02, 2019
DYNATRONICS CORPDYNT · Entity 73792	10% owner	October 30, 2025	October 30, 2025
IDEXX LABORATORIES INC /DEIDXX · Entity 3057	Director	May 12, 2026	May 14, 2026
INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707	Director · President and CEO	June 01, 2026	June 03, 2026
Orthofix Medical Inc.OFIX · Entity 1975	Director	January 05, 2023	February 09, 2023
PIPER SANDLER COMPANIESPIPR · Entity 3863	Director	May 20, 2026	May 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACCENDRA HEALTH INC/VA/

Report date June 28, 2019 · Filed July 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	60,853	Reported balance After 2019-06-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-28 · Grant · Acquired 48 · Balance 60,853 F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2: Shares acquired through quarterly dividend reinvestment transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d).

F2: Shares acquired through quarterly dividend reinvestment transaction.

DYNATRONICS CORP

Report date October 30, 2025 · Filed October 30, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,533,824	Reported balance After 2025-10-30 transaction · row 1 1 source row Row 1 · 2025-10-30 · Other · Acquired 13,405 · Balance 4,533,824 F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	891,112	Reported balance After 2025-10-30 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-10-30 · Other · Acquired 2,690 · Balance 891,112 F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25.

Filing footnotes · ownership attribution and instrument terms

F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25.

IDEXX LABORATORIES INC /DE

Report date May 12, 2026 · Filed May 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $533.92 · Expires 2036-05-11	Direct	525	Reported balance After 2026-05-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-12 · Grant · Acquired 525 · Balance 525 F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	234	Reported balance After 2026-05-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-12 · Grant · Acquired 234 · Balance 234 F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

INTEGRA LIFESCIENCES HOLDINGS CORP

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.67 · Expires 2034-06-01	Direct	705,468	Reported balance After 2026-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-01 · Grant · Acquired 705,468 · Balance 705,468 F1: This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	365,297	Reported balance After 2026-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-01 · Grant · Acquired 365,297 · Balance 365,297 F2: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3: This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.

F2: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3: This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.

Orthofix Medical Inc.

Report date January 05, 2023 · Filed February 09, 2023 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	205,966	Reported balance After 2023-01-05 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2023-01-05 · Grant · Acquired 14,354 · Balance 205,966 F1: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders. F2: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023. F3: Includes 14,354 deferred stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders.

F2: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023.

F3: Includes 14,354 deferred stock units.

PIPER SANDLER COMPANIES

Report date May 20, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,575	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 1,875 · Balance 2,575

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ST JUDE MEDICAL, LLC

Report date January 04, 2017 · Filed January 06, 2017

Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-01-04 transaction · row 1 1 source row Row 1 · 2017-01-04 · Disposition to issuer · Disposed 48,777 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.45 · Expires 2017-05-08	Direct	Reported balance After 2017-01-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.45 · Expires 2017-05-08	Direct	Reported balance After 2017-01-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-01-04 · Disposition to issuer · Disposed 2,250 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.15 · Expires 2018-05-07	Direct	Reported balance After 2017-01-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.15 · Expires 2018-05-07	Direct	Reported balance After 2017-01-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-01-04 · Disposition to issuer · Disposed 600 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.17 · Expires 2019-05-12	Direct	Reported balance After 2017-01-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-01-04 · Disposition to issuer · Disposed 9,700 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2020-05-03	Direct	Reported balance After 2017-01-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2020-05-03	Direct	Reported balance After 2017-01-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-01-04 · Disposition to issuer · Disposed 5,400 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.

F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

SeaSpine Holdings Corp

Report date January 05, 2023 · Filed January 10, 2023

Section 16 reporting ended · disclosed 2023-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-01-05 transaction · row 1 1 source row Row 1 · 2023-01-05 · Disposition to issuer · Disposed 460,275 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 191,612 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.68 · Expires 2025-08-01	Direct	Reported balance After 2023-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-05 · Disposition to issuer · Disposed 98,198 · Balance 0 F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 40,879 shares of Orthofix at a price of $37.67 per share. F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.18 · Expires 2026-01-01	Direct	Reported balance After 2023-01-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-05 · Disposition to issuer · Disposed 6,944 · Balance 0 F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 2,890 shares of Orthofix at a price of $41.27 per share. F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2026-06-07	Direct	Reported balance After 2023-01-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-05 · Disposition to issuer · Disposed 25,056 · Balance 0 F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 10,430 shares of Orthofix at a price of $24.00 per share. F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 191,612 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.

F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.

F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 40,879 shares of Orthofix at a price of $37.67 per share.

F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.

F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 2,890 shares of Orthofix at a price of $41.27 per share.

F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.

F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 10,430 shares of Orthofix at a price of $24.00 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2026 Filed Jun 3, 2026 20:54 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantRestricted Stock Units · Derivative	365,297	$0.00	$0.00	Disclosure SEC source: 0001187574-26-000008 · wk-form4_1780520095.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,297 Underlying: Common Stock · 365,297 shares Expires not disclosed F2 · derivative.exercise_price: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates. F3 · derivative.expiration_date: This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document
June 01, 2026 Filed Jun 3, 2026 20:54 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantNon-Qualified Stock Option (right to buy) · Derivative	705,468	$0.00 Strike: $15.67	$0.00	Disclosure SEC source: 0001187574-26-000008 · wk-form4_1780520095.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705,468 Underlying: Common Stock · 705,468 shares Expires 2034-06-01 F1 · derivative.exercise_date: This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document
May 20, 2026 Filed May 21, 2026 20:06 UTC	PIPER SANDLER COMPANIES PIPR · Entity 3863	GrantCommon Stock	1,875	$0.00	$0.00	Disclosure SEC source: 0001187574-26-000006 · wk-form4_1779393991.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,575 Read SEC document
May 12, 2026 Filed May 14, 2026 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	234	$0.00	$0.00	Disclosure SEC source: 0000874716-26-000101 · wk-form4_1778792420.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234 Underlying: Common Stock · 234 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 12, 2026 Filed May 14, 2026 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	525	$0.00 Strike: $533.92	$0.00	Disclosure SEC source: 0000874716-26-000101 · wk-form4_1778792420.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525 Underlying: Common Stock · 525 shares Expires 2036-05-11 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. Read SEC document
February 04, 2026 Filed Feb 5, 2026 23:08 UTC	PIPER SANDLER COMPANIES PIPR · Entity 3863	GrantCommon Stock	175	$0.00	$0.00	Disclosure SEC source: 0001187574-26-000004 · wk-form4_1770332910.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175 Read SEC document
October 30, 2025 Filed Oct 30, 2025 09:10 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	2,690	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-016387 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 891,112 F1 · price: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25. Read SEC document
October 30, 2025 Filed Oct 30, 2025 09:10 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	13,405	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-016387 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,533,824 F1 · price: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25. Read SEC document
October 01, 2025 Filed Oct 3, 2025 08:11 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	192,806	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-015908 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 888,422 F1 · price: $0.0593 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
October 01, 2025 Filed Oct 3, 2025 08:11 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	960,655	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-015908 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,520,419 F1 · price: $0.0593 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
August 14, 2025 Filed Aug 18, 2025 20:43 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	OtherCommon Stock	200,000	$13.62	$2,724,000.00	Disclosure SEC source: 0000917520-25-000078 · wk-form4_1755549813.xml · nonDerivative · entry 5 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Grantor Trust Disclosed balance after: 200,000 Read SEC document
August 14, 2025 Filed Aug 18, 2025 20:43 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	OtherCommon Stock	200,000	$13.62	$2,724,000.00	Disclosure SEC source: 0000917520-25-000078 · wk-form4_1755549813.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152,236 F1 · balance_after: On August 14, 2025, the reporting person transferred 200,000 shares of common stock to a grantor trust for which his spouse is the trustee. In exchange for the shares, the trust transferred assets to the reporting person with a fair market value equal to the transferred shares. The transfer of shares to the trust resulted in a decrease in the number of shares the reporting person beneficially owns directly and a corresponding increase in the number of shares the reporting person beneficially owns indirectly through the trust. F2 · balance_after: On August 8, 2025, in accordance with the provisions of a grantor retained annuity trust ("GRAT E"), 180,080 shares of common stock were distributed from GRAT E to the reporting person as an annuity payment in accordance with the terms of GRAT E. F3 · balance_after: On August 8, 2025, in accordance with the provisions of a grantor retained annuity trust ("GRAT F"), 500,000 shares of common stock were distributed from GRAT F to the reporting person as an annuity payment in accordance with the terms of GRAT F. The amount of shares available for distribution were insufficient to satisfy the full amount of the annuity payment obligation and so GRAT F was terminated, in accordance with the terms of GRAT F, following the completion of the foregoing distribution. Read SEC document
July 01, 2025 Filed Jul 2, 2025 08:03 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	174,652	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-012412 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 695,616 F1 · price: $0.0655 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 01, 2025 Filed Jul 2, 2025 08:03 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	870,203	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-012412 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,559,764 F1 · price: $0.0655 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
May 09, 2025 Filed May 13, 2025 20:16 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	24,898	$0.00	$0.00	Disclosure SEC source: 0000917520-25-000043 · wk-form4_1747167350.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director · Exec. Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,156 Read SEC document
May 09, 2025 Filed May 13, 2025 20:16 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	6,939	$0.00	$0.00	Disclosure SEC source: 0000917520-25-000043 · wk-form4_1747167350.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director · Exec. Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,258 F1 · balance_after: In accordance with the provisions of a Grantor Retained Annuity Trust, 152,397 shares were distributed from the GRAT to the reporting person. Read SEC document
May 07, 2025 Filed May 8, 2025 23:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantDeferred Stock Unit · Derivative	257	$0.00	$0.00	Disclosure SEC source: 0000874716-25-000078 · wk-form4_1746745246.xml · derivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Underlying: Common Stock · 257 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F3 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F3 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. Read SEC document
May 07, 2025 Filed May 8, 2025 23:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	600	$0.00 Strike: $486.61	$0.00	Disclosure SEC source: 0000874716-25-000078 · wk-form4_1746745246.xml · derivative · entry 3 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2035-05-06 F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 06, 2025 Filed May 8, 2025 23:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	262	$0.00	$0.00	Disclosure SEC source: 0000874716-25-000078 · wk-form4_1746745246.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 06, 2025 Filed May 8, 2025 23:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	262	$0.00	$0.00	Disclosure SEC source: 0000874716-25-000078 · wk-form4_1746745246.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2025 Filed Apr 3, 2025 15:09 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	123,529	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-006961 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 520,964 F1 · price: $0.0926 per share, payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
April 01, 2025 Filed Apr 3, 2025 15:09 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	615,485	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-006961 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,689,561 F1 · price: $0.0926 per share, payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 02, 2025 Filed Jan 6, 2025 14:08 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-000366 · form4.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 31,124 F2 · price: $0.1212 per share, shares issued as s compensation for services as a Director of the Issuer, valued at the closing price as of December 31, 2024 Read SEC document
January 02, 2025 Filed Jan 6, 2025 14:08 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	105,610	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-000366 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 397,435 F1 · price: $0.1083 per share, payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 02, 2025 Filed Jan 6, 2025 14:08 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	526,200	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-000366 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,074,076 F1 · price: $0.1083 per share, payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
October 01, 2024 Filed Oct 3, 2024 14:15 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	92,810	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-017362 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 291,825 F1 · price: $0.1233 per share, payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
October 01, 2024 Filed Oct 3, 2024 14:15 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	462,423	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-017362 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,547,876 F1 · price: $0.1233 per share, payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
August 15, 2024 Filed Aug 15, 2024 15:36 UTC	DYNATRONICS CORP DYNT · Entity 73792	GrantCommon Stock	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-015158 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 29,124 F1 · price: Shares issued as compensation for services as a director of the Issuer, valued at $0.20 Read SEC document
July 01, 2024 Filed Jul 5, 2024 17:00 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	39,311	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-013459 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 199,015 F1 · price: Payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 01, 2024 Filed Jul 5, 2024 17:00 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	195,861	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-013459 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,085,453 F1 · price: Payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
May 23, 2024 Filed May 24, 2024 20:08 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	PurchaseCommon Stock	52,641	$28.49	$1,499,978.97	Disclosure SEC source: 0000917520-24-000076 · wk-form4_1716581267.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director · Exec. Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,922 F1 · price: The price shown above represents the weighted average price of the shares purchased. The range of the purchase prices was $28.31 to $28.66 The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document
May 09, 2024 Filed May 13, 2024 20:59 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	10,672	$0.00	$0.00	Disclosure SEC source: 0000917520-24-000071 · wk-form4_1715633967.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director · Exec. Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 935,281 Read SEC document
May 09, 2024 Filed May 13, 2024 20:59 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	3,163	$0.00	$0.00	Disclosure SEC source: 0000917520-24-000071 · wk-form4_1715633967.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director · Exec. Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 924,609 Read SEC document
May 06, 2024 Filed May 8, 2024 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	257	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000100 · wk-form4_1715209288.xml · derivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 06, 2024 Filed May 8, 2024 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	262	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000100 · wk-form4_1715209288.xml · derivative · entry 3 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 06, 2024 Filed May 8, 2024 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	609	$0.00 Strike: $476.87	$0.00	Disclosure SEC source: 0000874716-24-000100 · wk-form4_1715209288.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 609 shares Expires 2034-05-05 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 06, 2024 Filed May 8, 2024 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	257	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000100 · wk-form4_1715209288.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2024 Filed Apr 3, 2024 15:07 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	29,096	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-007884 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 159,704 F1 · price: Payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
April 01, 2024 Filed Apr 3, 2024 15:07 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	144,968	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-007884 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 889,592 F1 · price: Payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 02, 2024 Filed Jan 4, 2024 12:11 UTC	DYNATRONICS CORP DYNT · Entity 73792	GrantCommon Stock	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-000354 · form4.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 27,124 F2 · price: Shares issued as compensation for services as a director of the Issuer, valued at $0.56 Read SEC document
January 02, 2024 Filed Jan 4, 2024 12:11 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	23,309	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-000354 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 130,608 F1 · price: Payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 02, 2024 Filed Jan 4, 2024 12:11 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	116,134	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-000354 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,624 F1 · price: Payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
October 03, 2023 Filed Oct 5, 2023 19:57 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	17,938	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-019100 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 107,299 F1 · price: Payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
October 03, 2023 Filed Oct 5, 2023 19:57 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	89,371	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-019100 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 628,490 F1 · price: Payment of quarterly dividend on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 06, 2023 Filed Jul 7, 2023 17:53 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	15,688	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-014736 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 26,734 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 06, 2023 Filed Jul 7, 2023 17:53 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	78,166	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-014736 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,793 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 06, 2023 Filed Oct 4, 2023 15:02 UTC Amendment	DYNATRONICS CORP DYNT · Entity 73792	GrantCommon Stock	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-018971 · form4a.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Spouse Disclosed balance after: 25,124 F2 · price: Transaction inadvertently omitted from original filing. Shares issued to Reporting Person's spouse as compensation for services as a director of the Issuer, valued at $0.75. Read SEC document
July 06, 2023 Filed Oct 4, 2023 15:02 UTC Amendment	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	15,688	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-018971 · form4a.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 89,361 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F3 · balance_after: Shares Owned: The reported value following this transaction is reflective of an administrative correction to the value reported on July 7, 2023. Read SEC document
July 06, 2023 Filed Oct 4, 2023 15:02 UTC Amendment	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	78,166	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-018971 · form4a.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,119 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F3 · balance_after: Shares Owned: The reported value following this transaction is reflective of an administrative correction to the value reported on July 7, 2023. Read SEC document
May 17, 2023 Filed May 19, 2023 21:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	257	Not disclosed	Not disclosed	Disclosure SEC source: 0000874716-23-000078 · wf-form4_168453009809122.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Underlying: Common Stock · 257 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.